Status:
WITHDRAWN
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)
Lead Sponsor:
Finch Research and Development LLC.
Conditions:
Autism Spectrum Disorder
Autism
Eligibility:
All Genders
5-17 years
Phase:
PHASE2
Brief Summary
Adolescent autism spectrum disorder subjects with associated GI symptoms will be randomized to receive oral dosing of CP101 capsules in Treatment Group I or matching placebo capsules in Treatment Grou...
Detailed Description
This is a Randomized Double-Blind Placebo Controlled Study of CP101 (Full-Spectrum Microbiota®) in Children with Autism Spectrum Disorder and Associated Gastrointestinal Symptoms
Eligibility Criteria
Inclusion
- Male or Female ages 5 to 17
- Diagnosis of ASD by health care provider
- CARS-2 score ≥35 by the study evaluator
- 1 year history of chronic abnormal bowel function with/without GI symptoms
- GSRS/Constipation sub-score ≥3.0, or/and GSRS/diarrhea sub-score ≥3.0, during Screening
Exclusion
- Inability to ingest intact capsules.
- Change or anticipated change of prescription medications and/or nutrition supplement and/or therapy to treat ASD symptoms
- Prior history, evidence, or diagnosis of inflammatory bowel disease or chronic autoimmune GI disease
- Below 5th percentile for weight on Centers for Disease Control and Prevention (CDC) growth chart based on age
- History of fecal microbiota transplantation (FMT) for any condition, regardless of route of administration within 12 months of Screening, or plan to undergo during the study
- History of epilepsy or any other seizure (except febrile seizure) disorder.
- Enrollment in any other investigational drug or device study within 8 weeks prior to investigational study medication (CP101/placebo) administration or within 5 half-lives of the last dose of the previous investigational compound, whichever is longer.
- Major intra-abdominal surgery within the past 60 days prior to Screening (excluding appendectomy or cholecystectomy) and/or planned invasive surgery/hospitalization during the study.
- Use of systemic antibiotics, systemic antiviral, or systemic antifungal (non-topical) for any condition during 8 weeks prior to Screening, or any anticipated use of above for any condition (e.g., frequent otitis media requiring antibiotics) before EOT (Week 24).
- Recent change or anticipated change of non-dietary probiotics.
- Any clinically significant condition that would jeopardize the safety or rights of the subject, or would confound the results of the study, in the opinion of the Principal Investigator.
- Clinically significant laboratory abnormalities at Screening at the discretion of the Principal Investigator.
- Pregnant, breast-feeding, or positive pregnancy test at Screening (for females of child-bearing potential) or for sexually active subjects (as determined by the Principal Investigator), who refuses to practice an acceptable form of birth control for the duration of the study.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03829878
Start Date
May 1 2020
End Date
December 1 2021
Last Update
April 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.